Pharmaceutical Services Regulations (Northern Ireland) 1997

• (6) In any other case the National Appeal Panel shall be convened in accordance with Part IV and shall thereafter determine the appeal.

PART II — PHARMACY PRACTICES COMMITTEE

Establishment

5

The Board shall appoint a committee (“the Pharmacy Practices Committee”) and the provisions of Part III shall apply to the proceedings of that committee.

Functions

6

The Pharmacy Practices Committee shall, on behalf of the Board, exercise the function of the Board under regulation 6(9) in accordance with paragraph 2(6).

Membership

7

• (1) The Pharmacy Practices Committee shall consist of 7 members of whom—

• (a) 2 shall be the chairman and vice-chairman respectively and be appointed as such by the Board; the chairman shall be a member of the Board, appointed, under paragraph 3(1)(a) or (b) of Schedule 1 to the Order, and neither shall be a doctor, dentist, ophthalmic optician, pharmacist, or a person or the employee of a person whose name is included in the pharmaceutical list;

• (b) 3 shall be pharmacists of whom—

• (i) one shall be a pharmacist whose name is not included in the pharmaceutical list and who is not the employee of a person whose name is included in that list; and he shall be appointed by the Board from persons nominated by the Pharmaceutical Society of Northern Ireland; and

• (ii) 2 shall be pharmacists each of whom is included in the pharmaceutical list or is an employee of a person whose name is included in that list; and each shall be appointed by the Board from persons nominated by such organisation which is, in the opinion of the Board, representative of the general body of chemists; and

• (c) 2 shall be appointed by the Board but neither shall be a pharmacist or a person, or employee of a person, whose name is included in the pharmaceutical list, or be a doctor who is required to supply drugs or appliances in terms of regulation 12; and not more than one of the 2 members so appointed shall be a doctor, dentist or ophthalmic optician.

• (2) Persons to act as deputies for, and corresponding in number to, each of those categories of person appointed pursuant to sub-paragraph (1)(b)(i), (b)(ii) and (c) shall, provided they satisfy the criteria specified in the relevant sub-paragraph, be appointed by the Board, and in the absence of any of those persons a deputy from the appropriate category shall be entitled to act in his place.

• (3) If a nomination sought for the purposes of sub-paragraph (1)(b)(i) or (ii) is not made before such date as the Board may determine, the Board may appoint as a member a person who satisfies the criteria specified in the relevant sub-paragraph.

8

The Board shall prepare and maintain lists of the persons who have been appointed, in accordance with paragraph 7(1)(a) or (b)(i) or (b)(ii) or (c) as the case may be, and who currently serve as members of the Pharmacy Practices Committee, and shall provide the Department with a copy of such lists.

PART III — PROCEDURE AT MEETINGS OF THE PHARMACY PRACTICES COMMITTEE

Declaration of interest

9

• (1) Before any meeting of the Pharmacy Practices Committee begins the chairman, or vice-chairman if acting as chairman, shall ask the members intending to be present whether, in respect of any matter to be considered at the meeting any of them—

• (a) has an interest to declare; or

• (b) is associated with a person who has such interest,

and any such member who has or, as the case may be, is associated with a person who has any such interest shall declare it accordingly.

• (2) Any member who has, pursuant to the provisions of sub-paragraph (1), declared an interest or who, in the opinion expressed to the meeting, of the chairman or vice-chairman if acting as chairman as the case may be, should have declared such an interest, shall not be present at the consideration or discussion of that matter or the voting on it, and a deputy who has no such interest may act in his place.

Quorum

10

No business shall be transacted at a meeting of the Pharmacy Practices Committee unless the chairman or vice-chairman acting as chairman, one member appointed under each of paragraph 7(1)(b)(i) and (ii) and 2 other members appointed under paragraph 7(1)(a) or (c) are present.

Voting and notification of decision

11

• (1) Subject to sub-paragraphs (2), (3) and (4), every application considered by the Pharmacy Practices Committee shall be considered by all members present, but be determined only by a majority of votes of the members present who are entitled to vote.

• (2) Any member appointed by virtue of paragraph 7(1)(b)(i) or 7(1)(c) and the vice-chairman, provided he is not acting as chairman, are entitled to vote.

• (3) A member appointed by virtue of paragraph 7(1)(b)(ii) is not entitled to vote and shall withdraw immediately before a decision on an application by voting takes place.

• (4) The chairman, or vice-chairman if acting as chairman, shall not be entitled to vote at any meeting except in the case of an equality of votes of the other persons present and voting, in which case he shall have a casting vote.

• (5) The Pharmacy Practices Committee shall within 5 working days of making its decision give written notification of it to the Board together with reasons therefor.

Standing Orders

12

Subject to the provisions of these Regulations, the Board may make, vary or revoke standing orders with respect to the terms of office of members of the Pharmacy Practices Committee, the procedure of that committee and the making of reports of its proceedings to the Board.

Effect of vacancy or defect in appointment

13

The proceedings of the Pharmacy Practices Committee shall not be invalidated by any vacancy in its membership, or any defect in a member's appointment.

PART IV — NATIONAL APPEAL PANEL

Nominees for the National Appeal Panel

14

• (1) The Board shall submit the names of its nominees for the National Appeal Panel to the Department and shall advise of any changes in such nominees.

• (2) The Department shall request the Pharmaceutical Society of Northern Ireland and such organisation which is, in the opinion of the Department, representative of the general body of chemists, to submit to the Department their nominees for the National Appeal Panel.

Chairman and Vice-Chairman of National Appeal Panel

15

• (1) After consultation with all Boards, the Pharmaceutical Society of Northern Ireland and such organisation which is, in the opinion of the Department, representative of the general body of chemists, the Department shall appoint persons as chairman and vice-chairman of the National Appeal Panel.

• (2) The persons appointed in accordance with sub-paragraph (1) shall not be a doctor, dentist, ophthalmic optician, pharmacist, or a person or employee of a person whose name is included in the pharmaceutical list.

Membership

16

• (1) In any case in which paragraph 4(6) applies, the Department shall arrange to convene in accordance with this paragraph the National Appeal Panel, the members of which shall be drawn from—

• (a) the lists maintained in accordance with paragraph 8; and

• (b) the nominees mentioned in paragraph 14.

• (2) A member of the National Appeal Panel shall not be a member of—

• (a) the Board or the Pharmacy Practices Committee which considered the application; or

• (b) any Board which was notified in accordance with paragraph 1(1)(d) and which submitted representations in accordance with that paragraph.

• (3) The National Appeal Panel shall consist of 9 members of whom—

• (a) one shall be chairman appointed in accordance with paragraph 15;

• (b) one shall be vice-chairman and likewise be appointed as such in accordance with paragraph 15;

• (c) 4 shall be pharmacists one of whom has been nominated by the Pharmaceutical Society of Northern Ireland and the other 3 by such organisation which is, in the opinion of the Department, representative of the general body of chemists; and of those 4 members only 2 shall be persons whose names are, or who are employees of persons whose names are, included in the pharmaceutical list; and

• (d) 3 shall have been nominated by a Board, but none shall be a pharmacist or a person, or employee of a person, whose name is included in the pharmaceutical list, or be a doctor who is required to supply drugs and appliances under regulation 12; and not more than one of those 3 shall be a doctor, dentist or ophthalmic optician.

Declaration of interest

17

• (1) Before the start of any meeting of the National Appeal Panel the chairman, or vice-chairman if acting as chairman, shall ask the members intending to be present whether, in respect of the appeal to be considered at the meeting, any of them—

• (a) has an interest to declare; or

• (b) is associated with a person who has such interest,

and any such member who has or, as the case may be, is associated with a person who has, any such interest shall declare it accordingly.

• (2) Any member who has, pursuant to sub-paragraph (1), declared an interest or who, in the opinion, expressed to the meeting, of the chairman or vice-chairman as the case may be, should have declared such an interest, shall not be present at the consideration or discussion of that appeal or the voting on it.

Quorum

18

No business of the National Appeal Panel shall be transacted unless the chairman, or vice-chairman if acting as chairman, and 2 members who are appointed under paragraph 16(3)(c) and are entitled to vote, and 2 members appointed under paragraph 16(3)(d) are present.

Voting

19

• (1) Subject to sub-paragraphs (2), (3) and (4), every appeal considered by the National Appeal Panel shall be considered by all members present, but be determined only by a majority of votes of the members present who are entitled to vote.

• (2) A member appointed in accordance with paragraph 16(3)(c) and whose name is not included in the pharmaceutical list and who is not an employee of a person whose name is included in that list, and the vice-chairman, provided he is not acting as chairman, are entitled to vote.

• (3) A member—

• (a) who is appointed in accordance with paragraph 16(3)(c) and whose name is included in the pharmaceutical list, or who is an employee of a person whose name is included in that list; or

• (b) who is appointed by virtue of paragraph 16(3)(d),

is not entitled to vote and shall withdraw immediately before a decision on an appeal by voting takes place.

• (4) The chairman, or vice-chairman if acting as chairman, shall not be entitled to vote at any meeting except in the case of an equality of votes of the other persons present and voting, in which case he shall have a casting vote.

Decisions by the National Appeal Panel

20

• (1) The National Appeal Panel shall determine an appeal in such manner as it thinks fit and may, if it considers that oral representations are unnecessary, determine the appeal without hearing any oral representations, and its decision in respect of that appeal shall be final.

• (2) The National Appeal Panel shall, within 5 working days of making its decision, give written notification of that decision together with reasons therefor to the Board to whom the application was made.

• (3) The Board shall, within 14 days of receipt of such notification, notify the applicant and all persons mentioned in paragraph 1 of that decision together with the reasons therefor.

SCHEDULE 5 — PHARMACEUTICAL COMMITTEE

1

The Pharmaceutical Committee constituted by the Agency after consultation with the Boards and such organisation which is, in the opinion of the Agency, representative of the general body of chemists and such other persons as it considers appropriate, shall consist of a chairman and such number of other members as the Agency thinks fit.

2

The chairman shall be a pharmacist appointed by the Department.

3

The term of office of members shall be determined by the Agency.

4

Where the place of a member becomes vacant before the expiration of his term of office whether by death, resignation or otherwise, the vacancy shall be filled by the Agency after consultation in accordance with paragraph 1 and if necessary with the Pharmaceutical Committee and any other person so appointed shall hold office for the remainder of the term of office of the member who died, resigned or otherwise vacated his office as the case may be.

5

A member of the Pharmaceutical Committee may resign his membership by giving to the Agency notice in writing.

6

Where any member of the Pharmaceutical Committee—

• (a) is absent from the meetings of the Committee for more than 6 months consecutively (except for a reason approved by the Agency);

• (b) has become bankrupt or has made a composition with his creditors; or

• (c) is convicted of an indictable offence;

the Agency shall forthwith by resolution, declare the office to be vacant and shall notify that fact in such manner as it thinks fit and thereupon the office shall become vacant.

7

A member of the Pharmaceutical Committee may vote upon any matter which touches the interests of members of his profession (himself included) but shall not vote upon any matters touching only his individual professional interests.

8

The proceedings of the Pharmaceutical Committee shall not be invalidated by any vacancy in the membership of the Committee or by any defect in the appointment of its members.

9

A member of the Pharmaceutical Committee who is a member of a Board shall cease to be a member of that Committee if he ceases to be a member of that Board.

Signed

Sealed with the Official Seal of the Department of Health and Social Services on 15th August 1997.

Joan Dixon — Assistant Secretary

Sealed with the Official Seal of the Department of Finance and Personnel on 15th August 1997.

D. Thomson — Assistant Secretary

Editorial notes

[^key-91a28c68ff99fd864b91b6294b122102]: Reg. 1 in operation at 6.10.1997, see reg. 1

[^key-167af3e976c4d341a71c982e28649465]: Reg. 2 in operation at 6.10.1997, see reg. 1

[^key-2b5d5b184b17cc3795f9305faeb6054f]: Reg. 3 in operation at 6.10.1997, see reg. 1

[^key-5e973f85fdc3c2bb73302b418ddb2609]: Reg. 4 in operation at 6.10.1997, see reg. 1

[^key-ca2c9b59425416921d1076c092ca23c8]: Reg. 5 in operation at 6.10.1997, see reg. 1

[^key-5cfae9e1e6b80f8ea669896f7634cccc]: Reg. 6 in operation at 6.10.1997, see reg. 1

[^key-fe07a192e9a0ba704c68655683761e2d]: Reg. 7 in operation at 6.10.1997, see reg. 1

[^key-a06a872a974d115383eedb9363d1bc5c]: Reg. 8 in operation at 6.10.1997, see reg. 1

[^key-cdd3bc3f63ededa245782c91591f4db9]: Reg. 9 in operation at 6.10.1997, see reg. 1

[^key-421c9df28ea6ece5aca67df30d0f418c]: Reg. 10 in operation at 6.10.1997, see reg. 1

[^key-1ad98b7549b28f164234b162669ad3fa]: Reg. 11 in operation at 6.10.1997, see reg. 1

[^key-66c2a429d9595202b227f2b198febbf7]: Reg. 12 in operation at 6.10.1997, see reg. 1

[^key-4391e0eabdee6bb155a1ec47eedf2cad]: Reg. 13 in operation at 6.10.1997, see reg. 1

[^key-ec383fe32ba48433f6edd486da6df9fb]: Reg. 14 in operation at 6.10.1997, see reg. 1

[^key-b39020f99b5cfeb8c1b4c1572effa5c7]: Reg. 15 in operation at 6.10.1997, see reg. 1

[^key-d4011aa9f56ba1aaa32a3f9bab18280a]: Reg. 16 in operation at 6.10.1997, see reg. 1

[^key-7ad5b10d7d0fed94c3eb2a47889b1153]: Reg. 17 in operation at 6.10.1997, see reg. 1

[^key-110555029dbc2795b5b02a7efb440071]: Sch. 2 para. 1 in operation at 6.10.1997, see reg. 1

[^key-ab3eee2779c7c7a4c6525255a13baa73]: Sch. 2 para. 2 in operation at 6.10.1997, see reg. 1

[^key-05bc52353cf55a904528381e65fb5de7]: Sch. 2 para. 3 in operation at 6.10.1997, see reg. 1

[^key-4546cf9d550b2c0f258c2dc289ab56a4]: Sch. 2 para. 4 in operation at 6.10.1997, see reg. 1

[^key-54a449cd9378aa145f46299e4f4b99c2]: Sch. 2 para. 5 in operation at 6.10.1997, see reg. 1

[^key-588f02f64f4000e68c8103260e14cb60]: Sch. 2 para. 6 in operation at 6.10.1997, see reg. 1

[^key-b73ffa515a218472e9d8cf79cda5ecb3]: Sch. 2 para. 7 in operation at 6.10.1997, see reg. 1

[^key-e159b9af8223c7885cc9dc929ece03bd]: Sch. 2 para. 8 in operation at 6.10.1997, see reg. 1

[^key-088e0326d44dd038222ae97977a5f642]: Sch. 2 para. 9 in operation at 6.10.1997, see reg. 1

[^key-8926dfdefbd6796082515148101d772c]: Sch. 2 para. 10 in operation at 6.10.1997, see reg. 1

[^key-9a1fa2e84410c7a39970953f14f3e468]: Sch. 2 para. 11 in operation at 6.10.1997, see reg. 1

[^key-0d67053f4d684649ef12fb30e68cf8e4]: Sch. 2 para. 12 in operation at 6.10.1997, see reg. 1

[^key-2b210a736fed640c4d43e961f4fee023]: Sch. 2 para. 13 in operation at 6.10.1997, see reg. 1

[^key-ac005cc718e41d98f5291749410186be]: Sch. 2 para. 14 in operation at 6.10.1997, see reg. 1

[^key-919d459974d935576ddcc35e4c71eb39]: Sch. 2 para. 15 in operation at 6.10.1997, see reg. 1

[^key-de434ea6bc99e6d353254528aa753928]: Sch. 2 para. 16 in operation at 6.10.1997, see reg. 1

[^key-49ed5a092518b05c554c2e522140ae81]: Sch. 2 para. 17 in operation at 6.10.1997, see reg. 1

[^key-4b1dea32fbb860149a9d8ea7b387c8ec]: Sch. 4 para. 1 in operation at 6.10.1997, see reg. 1

[^key-2b8988b19c18472f434b10b7e56c30a8]: Sch. 4 para. 2 in operation at 6.10.1997, see reg. 1

[^key-48c59d01ad800a228c2cbbbebab25e37]: Sch. 4 para. 3 in operation at 6.10.1997, see reg. 1

[^key-b1b94ce2d3df565f408ffc3676c8c159]: Sch. 4 para. 4 in operation at 6.10.1997, see reg. 1

[^key-6447e28bb18a73833ee83dd1fd8d26c8]: Sch. 4 para. 5 in operation at 6.10.1997, see reg. 1

[^key-1b1d1eeda596ea505ccbd78cf05b14b7]: Sch. 4 para. 6 in operation at 6.10.1997, see reg. 1

[^key-6952e89c38b63edeb5ac88237730abbb]: Sch. 4 para. 7 in operation at 6.10.1997, see reg. 1

[^key-d04bb5471cff6fd562c2f6ffd63f78c3]: Sch. 4 para. 8 in operation at 6.10.1997, see reg. 1

[^key-efe90a8cecff43d895a7c9ec4f691d58]: Sch. 4 para. 9 in operation at 6.10.1997, see reg. 1

[^key-689773c0ad835cfe43c1c7c8d18077dd]: Sch. 4 para. 10 in operation at 6.10.1997, see reg. 1

[^key-bb4b33d972abc0a5c3f20293348aab37]: Sch. 4 para. 11 in operation at 6.10.1997, see reg. 1

[^key-93cee89d2f776f1ada546d357426c7bf]: Sch. 4 para. 12 in operation at 6.10.1997, see reg. 1

[^key-60168fa4e3f4d4dd6b0041eec77400f7]: Sch. 4 para. 13 in operation at 6.10.1997, see reg. 1

[^key-9b4cd035b34cddde75503828e7250808]: Sch. 4 para. 14 in operation at 6.10.1997, see reg. 1

[^key-86c8862c58747c097ab914efff238131]: Sch. 4 para. 15 in operation at 6.10.1997, see reg. 1

[^key-5bb0fb095c65b7201dbda41183838689]: Sch. 4 para. 16 in operation at 6.10.1997, see reg. 1

[^key-d839960ee75b230fc91d4dd087690a1f]: Sch. 4 para. 17 in operation at 6.10.1997, see reg. 1

[^key-2e84659eed1af4ab42a9ce83284cfde9]: Sch. 4 para. 18 in operation at 6.10.1997, see reg. 1

[^key-22a8deb40e714447548fbd752bea1f83]: Sch. 4 para. 19 in operation at 6.10.1997, see reg. 1

[^key-4385551517db17e8be323235ffadf85a]: Sch. 4 para. 20 in operation at 6.10.1997, see reg. 1

[^key-f2cfc833025bad773135fa6b46499bbc]: Sch. 5 para. 1 in operation at 6.10.1997, see reg. 1

[^key-a69b70b6a9f7f6416b1250638290b667]: Sch. 5 para. 2 in operation at 6.10.1997, see reg. 1

[^key-e38efa7e3e244c2a2e7105a701b16732]: Sch. 5 para. 3 in operation at 6.10.1997, see reg. 1

[^key-843c878021e4bafe0bac4c23df8f392e]: Sch. 5 para. 4 in operation at 6.10.1997, see reg. 1

[^key-08aef3e0cebe986a968486d79ecfc0be]: Sch. 5 para. 5 in operation at 6.10.1997, see reg. 1

[^key-f3193bc5714f3fd2006934aa7d9a9455]: Sch. 5 para. 6 in operation at 6.10.1997, see reg. 1

[^key-bd8ff393572150a472dfb8ddd819bcbb]: Sch. 5 para. 7 in operation at 6.10.1997, see reg. 1

[^key-11b806ebf8654f5dc7fa49bf4be18774]: Sch. 5 para. 8 in operation at 6.10.1997, see reg. 1

[^key-f47b6ffc56a452f48d237b7b1491c5ef]: Sch. 5 para. 9 in operation at 6.10.1997, see reg. 1

[^key-a5d04a08b965caf830694d8ad0d025b1]: Sch. 1 in operation at 6.10.1997, see reg. 1

[^key-ad683e5be548539845407994831b6ecd]: Sch. 3 Pt. I in operation at 6.10.1997, see reg. 1

[^key-0f3d19533560d4464a9c4646bd688f1e]: Sch. 3 Pt. II in operation at 6.10.1997, see reg. 1

Explanatory note

(This note is not part of the Regulations.)

EXPLANATORY NOTE

These Regulations consolidate, with amendments, those provisions of the Health and Personal Social Services (General Medical and Pharmaceutical Services) Regulations (Northern Ireland) 1973 (“the 1973 Regulations”) which relate to pharmaceutical services. The provisions of the 1973 Regulations which relate to General Medical Services are consolidated with amendments, in the Health and Personal Social Services (General Medical Services) Regulations (Northern Ireland) 1997. These Regulations now regulate the terms on which pharmaceutical services are provided under the Health and Personal Social Services (Northern Ireland) Order 1972.

The Regulations make the following principal changes—

• (1) A chemist whose name is to be removed from the pharmaceutical list because pharmaceutical services have not been provided now has a right of appeal.

• (2) A right of appeal has been provided against the Board's determination of an application for a minor relocation of premises.

• (3) The terms of service now require a chemist to obtain the approval of the Board for the times at which he proposes to provide pharmaceutical services from the premises in respect of which he is included on the pharmaceutical list. Provision is made for the Board to grant approval subject to any conditions that it considers necessary to meet local needs. A chemist may apply for a variation of the approved times or of any condition and may appeal either against a refusal to approve his proposed times or against the imposition of any conditions.

• (4) The regulations contain terms of service for doctors who provide pharmaceutical services (Part III of Schedule 2).

Footnotes

[^f00001]: S.I. 1972 (N.I. 14)

[^f00002]: Article 63 is amended by Article 14 of S.I. 1978/1907 (N.I. 26); Article 5(1) of S.I. 1986/2023 (N.I. 20); regulation 4 of S.R. 1987 No. 457; Article 31 of S.I. 1991/194 (N.I. 1) and Article 3 of S.I. 1992/2671 (N.I. 18)

[^f00003]: 1968 c. 67

[^f00004]: S.R. 1996 No. 137

[^f00005]: Article 55 is amended by Article 5 of S.I. 1991/194 (N.l. 1)

[^f00006]: S.R. 1997 No. 380

[^f00007]: 1968 c. 67; section 103(5) is amended by section 22(6) of the Health and Medicines Act 1988 (c. 49)

[^f00008]: 14 & 15 Geo. 6 c. 65

[^f00009]: S.I. 1979/291

[^f00010]: 1980 c. 9

[^f00011]: Paragraphs 8A and 8B were inserted by Article 4 of S.I. 1995/2704 (N.l. 24)

[^f00012]: 1979 c. 36; the Parts of the professional register are determined by S.I. 1983/667, amended by S.I. 1989/104 and 1989/1455

[^f00013]: Approved by S.l. 1983/873, to which there are amendments not relevant to these Regulations

[^f00014]: S.I. 1991/194 (N.I. 1)

[^f00015]: 1954 c. 33 (N.l.)

[^f00016]: S.I. 1992/3204 (N.I. 20)

[^f00017]: S.R. 1997 No. 382

[^f00018]: S.I. 1976/1213 (N.I. 22) as amended by S.R. 1987 No. 457

[^f00019]: Paragraph 8B(3) of Schedule 11 is inserted by Article 4 of S.I. 1995/2704 (N.I. 24)

[^f00020]: S.R. & O. 1973 No. 421 as amended by S.R. 1987 No. 247

[^f00021]: S.I. 1972/1265 (N.I. 14)

[^f00022]: S.I. 1978/1907 (N.I. 26)

[^f00023]: S.I. 1986/2023 (N.I. 20)

[^f00024]: S.R. 1987 No. 457

[^f00025]: S.I. 1992/2671 (N.I. 18)

[^f00026]: S.I. 1986/2229 (N.I. 24)

[^f00027]: S.I. 1988/2249 (N.I. 24)

[^f00028]: 1968 c. 67

[^f00029]: 1988 c. 49

[^f00030]: S.R. 1983 No. 201; relevant amending Regulations are S.R. 1985 No. 345, S.R. 1987 No. 240 and S.R. 1994 No. 217

[^f00031]: S.R. 1986 No. 52; relevant amending Regulations are S.R. 1987 No. 68, S.R. 1988 No. 206, S.R. 1989 No. 346, S.R. 1991 No. 1, S.R. 1995 No. 305, S.R. 1995 No. 480 and S.R. 1996 No. 353

[^f00032]: 1971 c. 38

[^f00033]: S.R. & O. (N.I.) 1973 No. 1 80 as amended by S.R. 1984 No. 17

[^f00034]: Schedule 11 is amended by Article 3 of, paragraph 2 of Schedule 1 to, Article 17 of and Part I of Schedule 6 to S.I. 1984/1158 (N.I. 8) and Articles 3 to 6 of S.I. 1995/2704 (N.I. 14)

[^f00035]: Article 98 is amended by Article 34 of, and Part II of Schedule 5 to, S.l. 1991/194 (N.l. 1)

[^f00036]: S.I. 1995/755 (N.I. 2)